Particles for Humanity and Hexagon Nutrition Sign License Agreement
"By joining forces with Hexagon Nutrition, we can accelerate the production and distribution of this critical product, ensuring it reaches those who need vitamin A the most. Combining Particles for Humanity's research and development expertise with Hexagon's established global distribution network advances a shared goal: improving lives with stable vitamin A," said
In
Under this new partnership, Hexagon Nutrition will have 3-year exclusive rights to manufacture and distribute PFH-VAP for bouillon fortification. Together Hexagon Nutrition and Particles for Humanity are taking an important step to expand access to lifesaving micronutrients in
"Improving nutrition globally is at the core of our business. PFH-VAP will be another strong asset in our product portfolio. We are excited to leverage Hexagon Nutrition's ingredient manufacturing and premixing expertise to advance innovation and reduce the burden of malnutrition," said
Particles for Humanity transforms early-stage medical technology into products for people living in low and lower-middle income countries. Its rigorous product development process is based on end-user input. Particles for Humanity is funded solely with philanthropy and is focused on financially sustainable product opportunities. Visit www.particlesfh.com or contact [email protected]
Hexagon Nutrition is a differentiated and research-oriented pure-play nutrition company offering clinical nutrition solutions products, micronutrient premixes, and therapeutic products. Hexagon Nutrition has presence across retail pharmacies, hospitals, and prominent e-commerce players. Hexagon markets products across
View original content to download multimedia:https://www.prnewswire.com/news-releases/particles-for-humanity-and-hexagon-nutrition-sign-license-agreement-302414202.html
SOURCE Particles for Humanity
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
- Global EV Transition Continues to Drive Interest as ELEKTROS Advances Its Vision for Lithium, Critical Minerals and Charging Innovation
- New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share